Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMRVEHY)

Drug Name
LY3012212 Drug Info
Synonyms Icrucumab
Indication
Disease Entry ICD 11 Status REF
Arteriosclerosis BD40 Phase 2 [1]
Bladder cancer 2C94 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMRVEHY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor receptor 1 (FLT-1) TT2Q6G1 VGFR1_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vascular endothelial growth factor receptor 1 (FLT-1) DTT FLT1 4.802 4.95 4.597 3.17
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Arteriosclerosis
ICD Disease Classification BD40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor receptor 1 (FLT-1) DTT FLT1 3.48E-03 0.9 1.6
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024862)
2 Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.